文献速递肿瘤 PET/CT核素与放射性配体治疗

联合[18F]-氟乙基胆碱PET/CT与99mTc-大颗粒白蛋白SPECT/CT预测中期肝细胞癌患者生存

Combined [18F]-Fluoroethylcholine PET/CT and 99mTc-Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular Carcinoma.
PubMed 文献 · Clin Nucl Med · 2018-01-01

回顾性分析24例巴塞罗那临床肝癌B期肝细胞癌患者,在放射性栓塞前行[18F]FEC PET/CT与99mTc-MAA SPECT/CT检查。血管化肿瘤比率(高MAA和高FEC摄取)与生存显著相关,多因素分析中为显著预测因子(P=0.015;HR 11.65;95%CI 1.62-83.73)。血管化程度高的患者中位生存274±80天 vs 585±284天(P=0.015)。

要点

  • 血管化肿瘤比率是中期肝细胞癌放射性栓塞后生存的独立预测因子(P=0.015;HR 11.65)。
  • 血管化肿瘤比率预测1年生存的AUC为0.77(P=0.024), cutoff 9%时灵敏度83%、特异度67%。
  • 高肿瘤血管化患者中位生存274±80天 vs 585±284天(P=0.015)。

核心结论

  • 代谢活跃区域高血管化的肝细胞癌经联合FEC PET/CT与Tc-MAA SPECT/CT评估,代表放射性栓塞后总生存缩短的不利亚组。

研究设计与样本

  • 回顾性分析24例已知肝细胞癌巴塞罗那临床肝癌B期患者,均计划行放射性栓塞,治疗前接受[18F]FEC PET/CT和99mTc-MAA SPECT/CT用于肝肺分流评估。

主要发现

  • 所有患者(5例女性/19例男性)在观察期内均死亡,中位生存395天(±51天;范围23-1122天)。
  • 血管化肿瘤比率(定义为高MAA和高FEC摄取)与生存显著相关,单因素和多因素分析均为显著预测因子(P=0.026;风险比11.65;95%置信区间1.62-83.73;P=0.015)。
  • 多因素分析中所有其他变量均未达统计学显著。
  • 血管化肿瘤比率预测1年生存的ROC曲线下面积为0.77(P=0.024); cutoff值9%时,灵敏度、特异度、阳性和阴性预测值分别为83%、67%、71%和80%(P=0.036)。
  • 高肿瘤血管化患者中位生存274±80天 vs 585±284天(P=0.015)。

关键数值与推荐

  • 血管化肿瘤比率 cutoff值9%:灵敏度83%、特异度67%、阳性预测值71%、阴性预测值80%(P=0.036)。
  • 血管化肿瘤比率多因素分析:P=0.015;风险比11.65;95%置信区间1.62-83.73。
  • 血管化肿瘤比率预测1年生存AUC 0.77(P=0.024)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The aim of this study was to retrospectively analyze the prognostic value of combined Tc-macroaggregated albumin (MAA) SPECT/CT and [F]-fluoroethylcholine (FEC) PET/CT before radioembolization for survival of patients with intermediate-stage hepatocellular carcinoma. METHODS: Twenty-four patients with known hepatocellular carcinoma Barcelona Clinic Liver Cancer stage B were eligible for this analysis. All patients were scheduled for radioembolization and received a pretherapeutic [F]FEC PET/CT scan as well as Tc-MAA SPECT/CT for hepatopulmonary shunting. Laboratory and semiquantitative PET parameters and morphologic and metabolic (intersection) volumes of MAA and FEC were evaluated. Spearman correlation with overall survival, receiver operating curve analyses, univariate and multivariate Cox regression, and Kaplan-Meier-analysis was applied. RESULTS: All patients (5 female/19 male) are deceased within the observational period. Median survival was 395 days (±51 days; range, 23-1122 days). The percentage of hypervascularized metabolically active tumor volume (vascularized tumor ratio; defined as high MAA and FEC uptake) correlated significantly with survival. Vascularized tumor ratio was a significant predictor in univariate and multivariate analyses (P = 0.026; hazard ratio, 11.65; 95% confidence interval, 1.62-83.73; P = 0.015). Statistical significance was not reached by all other variables in multivariate analysis. Receiver operating curve analysis for 1-year survival revealed an area under the curve of 0.77 (P = 0.024) for vascularized tumor ratio. At a cutoff value of 9%, sensitivity, specificity, and positive and negative prediction were 83%, 67%, and 71% and 80% (P = 0.036). Patients with a higher tumor vascularization had a median survival of 274 ± 80 versus 585 ± 284 days (P = 0.015). CONCLUSIONS: Hepatocellular carcinoma with high vascularization in metabolic active areas as assessed by combined FEC PET/CT and Tc-MAA SPECT/CT represents an unfavorable subgroup with reduced overall survival after radioembolization.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hartenbach M, Weber S, Pilz M, et al. Combined [18F]-Fluoroethylcholine PET/CT and 99mTc-Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular Carcinoma. Clin Nucl Med. 2018. PMID: 29659390. doi:10.1097/RLU.0000000000002092

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。